Baseline features at IFX initiation and association with corticosteroid-free clinical remission after 12 weeks of IFX in multivariable logistic regression
| Feature | ORs | 95% CI | P value |
| Male gender | 0.69 | 0.29 to 1.63 | 0.40 |
| Age | 1.00 | 0.97 to 1.04 | 0.83 |
| Rectal bleeding | 0.19 | 0.04 to 0.80 | 0.03* |
| CTCAE grade for diarrhea | 1.88 | 0.99 to 3.71 | 0.06 |
| Ulcers on lower GI endoscopy | 0.66 | 0.25 to 1.70 | 0.40 |
| Combination CPI therapy | 1.10 | 0.46 to 2.66 | 0.83 |
| Lymphocytic infiltrate | 0.83 | 0.31 to 2.16 | 0.70 |
| Crypt abscesses | 2.93 | 1.13 to 8.05 | 0.03* |
| Apoptosis | 0.83 | 0.28 to 2.35 | 0.72 |
| Chronic active inflammation | 0.82 | 0.35 to 1.95 | 0.66 |
Significant factors with OR<1 or >1 predicted IFX resistance or IFX responsiveness, respectively.
*Statistical significance is indicated by <0.05.
CPI, checkpoint inhibitor; CTCAE, Common Terminology Criteria for Adverse Events; GI, gastrointestinal; IFX, infliximab.